Publication year
2004Author(s)
Source
Current Opinion in Molecular Therapeutics, 6, 4, (2004), pp. 451-7ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Surgery
Journal title
Current Opinion in Molecular Therapeutics
Volume
vol. 6
Issue
iss. 4
Page start
p. 451
Page end
p. 7
Subject
EBP 2: Effective Hospital Care; UMCN 1.3: Tumor microenvironment; UMCN 5.2: Endocrinology and reproductionAbstract
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.
This item appears in the following Collection(s)
- Academic publications [246216]
- Faculty of Medical Sciences [93266]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.